CO2022014867A2 - Composiciones farmacéuticas y productos farmacéuticos de interleucina–15 humana heterodimérica (hetil–15) - Google Patents
Composiciones farmacéuticas y productos farmacéuticos de interleucina–15 humana heterodimérica (hetil–15)Info
- Publication number
- CO2022014867A2 CO2022014867A2 CONC2022/0014867A CO2022014867A CO2022014867A2 CO 2022014867 A2 CO2022014867 A2 CO 2022014867A2 CO 2022014867 A CO2022014867 A CO 2022014867A CO 2022014867 A2 CO2022014867 A2 CO 2022014867A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceuticals
- pharmaceutical compositions
- hethyl
- human interleukin
- heterodimeric human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013801P | 2020-04-22 | 2020-04-22 | |
| PCT/IB2021/053254 WO2021214658A1 (en) | 2020-04-22 | 2021-04-20 | Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetil-15) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022014867A2 true CO2022014867A2 (es) | 2022-10-31 |
Family
ID=75639945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0014867A CO2022014867A2 (es) | 2020-04-22 | 2022-10-19 | Composiciones farmacéuticas y productos farmacéuticos de interleucina–15 humana heterodimérica (hetil–15) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210330747A1 (enExample) |
| EP (1) | EP4138782A1 (enExample) |
| JP (1) | JP2023523218A (enExample) |
| KR (1) | KR20230004655A (enExample) |
| CN (1) | CN115443127A (enExample) |
| AR (1) | AR122428A1 (enExample) |
| AU (1) | AU2021260989A1 (enExample) |
| BR (1) | BR112022020973A2 (enExample) |
| CA (1) | CA3178895A1 (enExample) |
| CO (1) | CO2022014867A2 (enExample) |
| IL (1) | IL297326A (enExample) |
| MX (1) | MX2022013352A (enExample) |
| TW (1) | TW202214290A (enExample) |
| WO (1) | WO2021214658A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117024749A (zh) | 2019-06-28 | 2023-11-10 | 国立大学法人东京大学 | 蛋白质内包高分子胶束 |
| TWI857396B (zh) * | 2021-11-18 | 2024-10-01 | 大陸商山東先聲生物製藥有限公司 | Il-15突變體融合蛋白藥物組合物 |
| IL322075A (en) * | 2023-02-14 | 2025-09-01 | Akron Bioproducts Llc | Pharmaceutical compositions of interleukin for use in vivo |
| CN117883565A (zh) * | 2023-12-25 | 2024-04-16 | 中山大学 | 沙美特罗和pd-1抗体联用在制备治疗黑色素瘤的药物中的应用 |
| WO2025206413A1 (en) * | 2024-03-28 | 2025-10-02 | The University Of Tokyo | Protein-enclosing polymeric complexes |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| EP3263581B2 (en) | 2005-05-17 | 2025-07-09 | University of Connecticut | Compositions and methods for immunomodulation in an organism |
| NZ569541A (en) | 2006-01-13 | 2012-05-25 | Us Gov Health & Human Serv | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
| CN101743249B (zh) | 2007-05-11 | 2017-08-08 | 阿尔托生物科学有限公司 | 融合分子与il‑15变异体 |
| CA2711984A1 (en) * | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co. Kg | Powdered protein compositions and methods of making same |
| CA2727953C (en) | 2008-08-22 | 2017-05-16 | Magna Seating Inc. | Disc recliner with reduced backlash |
| US8915886B2 (en) * | 2009-10-21 | 2014-12-23 | Owen Mumford Limited | Autoinjector |
| US8507222B2 (en) | 2010-09-21 | 2013-08-13 | Altor Bioscience Corporation | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
| EP3292873B1 (en) * | 2013-02-22 | 2019-05-01 | CureVac AG | Combination of vaccination and inhibition of the pd-1 pathway |
| ES2811974T3 (es) * | 2014-07-29 | 2021-03-15 | Novartis Ag | Regímenes de aumento escalonado de la dosis del heterodímero de il-15 e il-15ralfa para tratar afecciones |
| WO2017177063A1 (en) * | 2016-04-06 | 2017-10-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of heterodimeric il-15 in adoptive cell transfer |
| WO2019019998A1 (zh) * | 2017-07-25 | 2019-01-31 | 江苏恒瑞医药股份有限公司 | 一种il-15蛋白复合物药物组合物及其用途 |
| EP3810171B1 (en) * | 2018-06-22 | 2025-07-09 | Cugene Inc. | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
| JP2022530130A (ja) * | 2019-04-26 | 2022-06-27 | ルビウス セラピューティクス， インコーポレイテッド | 除核赤血球細胞を含む緩衝組成物 |
-
2021
- 2021-04-20 TW TW110114219A patent/TW202214290A/zh unknown
- 2021-04-20 JP JP2022563971A patent/JP2023523218A/ja active Pending
- 2021-04-20 AU AU2021260989A patent/AU2021260989A1/en active Pending
- 2021-04-20 CN CN202180030326.7A patent/CN115443127A/zh active Pending
- 2021-04-20 US US17/234,914 patent/US20210330747A1/en active Pending
- 2021-04-20 WO PCT/IB2021/053254 patent/WO2021214658A1/en not_active Ceased
- 2021-04-20 IL IL297326A patent/IL297326A/en unknown
- 2021-04-20 MX MX2022013352A patent/MX2022013352A/es unknown
- 2021-04-20 CA CA3178895A patent/CA3178895A1/en active Pending
- 2021-04-20 KR KR1020227040050A patent/KR20230004655A/ko active Pending
- 2021-04-20 EP EP21720852.9A patent/EP4138782A1/en active Pending
- 2021-04-20 BR BR112022020973A patent/BR112022020973A2/pt unknown
- 2021-04-22 AR ARP210101082A patent/AR122428A1/es unknown
-
2022
- 2022-10-19 CO CONC2022/0014867A patent/CO2022014867A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023523218A (ja) | 2023-06-02 |
| AU2021260989A1 (en) | 2022-11-17 |
| US20210330747A1 (en) | 2021-10-28 |
| KR20230004655A (ko) | 2023-01-06 |
| BR112022020973A2 (pt) | 2022-12-06 |
| MX2022013352A (es) | 2022-11-30 |
| CA3178895A1 (en) | 2021-10-28 |
| EP4138782A1 (en) | 2023-03-01 |
| IL297326A (en) | 2022-12-01 |
| AR122428A1 (es) | 2022-09-07 |
| CN115443127A (zh) | 2022-12-06 |
| WO2021214658A1 (en) | 2021-10-28 |
| TW202214290A (zh) | 2022-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022014867A2 (es) | Composiciones farmacéuticas y productos farmacéuticos de interleucina–15 humana heterodimérica (hetil–15) | |
| NI201900041A (es) | 1, 2, 4-triazolonas 2, 4, 5-trisustituidas | |
| UY37789A (es) | Nuevos derivados de azaquinolina | |
| CL2020002891A1 (es) | Nuevos derivados de quinolina | |
| DOP2019000117A (es) | Nuevos derivados de quinolina | |
| MX2020008208A (es) | Agentes de unión a fibroblastos y uso de estos. | |
| CO2018010966A2 (es) | Nuevos derivados de pirazolopirimidina | |
| CL2021000088A1 (es) | Anticuerpos anti-cd27 (divisional de solicitud 779-2019). | |
| CO2019009680A2 (es) | Anticuerpo anti-gprc5d y molécula que comprende el anticuerpo | |
| CO2020001244A2 (es) | Derivados de quinolina para tratar infecciones con helmintos | |
| CO2020001242A2 (es) | Dihidrooxadiazinonas | |
| CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
| CO2019011877A2 (es) | Nuevos derivados de pirazol bicíclicos | |
| CL2021001162A1 (es) | Proteínas de fusión fc il-22 y métodos de uso. (divisional de solicitud 202001944) | |
| UY37460A (es) | 1,2,4-triazolonas con anelación en 4 y 5 | |
| BR0208183A (pt) | Peptìdeo modificado por wt1 | |
| PA8595001A1 (es) | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) | |
| CO5640037A2 (es) | Derivados de la quinazolina para el tratamiento del cancer | |
| UY38816A (es) | Nuevos derivados de isoquinolina | |
| PY2056649A (es) | Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15ra y su uso | |
| BR112022004397A2 (pt) | Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos | |
| ECSP045353A (es) | Derivados de benzoxazinona, su preparación y aplicación como medicamentos | |
| ECSP23077322A (es) | Derivados de fósforo como nuevos inhibidores de sos1 | |
| MX2025004075A (es) | Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos | |
| UY27851A1 (es) | Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. |